AstraZeneca's Tozorakimab Succeeds in Two Phase 3 COPD Trials Where Rivals Failed, Validating IL-33 as a Drug Target
Tozorakimab becomes the first IL-33-targeting biologic to show statistically significant reductions in COPD exacerbations across two confirmatory Phase 3 trials, after competitors Sanofi and Roche stumbled in the same drug class.
4 min read3 sources